1 – 9 of 9
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
(
- Contribution to journal › Article
- 2008
-
Mark
Long Term Efficacy And Tolerability Of Anagrelide In Myeloproliferative Disorders
2008) 13th Congress of the European-Hematology-Association In Haematologica-The Hematology Journal 93. p.0746-0746(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Management of patients with polycythaemia vera: results of a survey among Swedish haematologists
(
- Contribution to journal › Article
-
Mark
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: Long-term follow-up
(
- Contribution to journal › Article
- 2004
-
Mark
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders
(
- Contribution to journal › Article
-
Mark
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival
(
- Contribution to journal › Article
- 2003
-
Mark
Mutated V-H genes and preferential V(H)3-21 use define new subsets of mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor: significant effects on quality of life
(
- Contribution to journal › Article
- 2002
-
Mark
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase - a report from the Swedish CML Group
(
- Contribution to journal › Article